



A harmonized PBPK model of hexavalent chromium in rats and mice

Society of Risk Analysis Annual Meeting

Baltimore, MD

Monday December 9th, 2013

Alan F. Sasso, PhD, Paul M. Schlosser, PhD

U.S. EPA Office of Research and Development

National Center for Environmental Assessment


The views expressed are those of the authors, and do not necessarily represent the views or policies of the U.S. EPA.

Overview


- Integrated Risk Information System (IRIS) background
- Hexavalent chromium toxicity and carcinogenicity
 - Toxicokinetics in the gastrointestinal (GI) tract
- Adaptation of toxicokinetic models
 - Updated kinetic model for GI metabolism
 - Revisions to whole-body model assumptions
- Application to National Toxicology Program data
- Remaining issues, Q&A

IRIS Program

- IRIS assessments critically review publicly available studies to:
 - Identify adverse health effects
 - Derive toxicity values



NRC risk assessment/risk management paradigm




Hexavalent Chromium (Cr VI)

- Cr(VI) has been detected in drinking water throughout US
 - Cr(VI) detected above 0.03 µg/L in ~75% of total samples (5260/6928)
 - MRL:0.03 ppb; Most under ~5 ppb
 - Source: US EPA Third Unregulated Contaminant Monitoring Rule Occurrence data (as of October 2013)
 - EPA is continuing to compile data from public water systems and this only represents about 15 % of the data expected under the UCMR
- Cr(VI) reduces to trivalent chromium (Cr III) in biological fluids
 - Cr(III) is poorly absorbed by cells, has limited toxicity
 - Rodents chronically exposed to Cr(VI) via drinking water show toxicity and carcinogenicity in the GI tract




National Toxicology Program (2008)

Female **MICE** exposed for 2 years to Cr(VI) in drinking water



National Toxicology Program (2008)

RATS exposed for 2 years to Cr(VI) in drinking water



Distal from
portal of
entry
(mouth)

No tumors, no distal
effects further along
GI tract

Evidence in humans is limited

- Zhang & Li (1987) and reanalysis (Beaumont et al., 2008)
 - Population in China chronically exposed to drinking water heavily contaminated with Cr(VI)
 - Currently the only study indicating elevated risk of stomach cancer in humans
- IARC determined this single study was insufficient to constitute evidence of an association between oral exposure to Cr(VI) and stomach cancer
 - **International Agency for Research on Cancer** (2012). IARC Monographs: *A review of human carcinogens: Arsenic, metals, fibres, and dusts.*


Physiologically-based pharmacokinetic (PBPK) modeling

- Modeling tools that can help explain similarities and differences in response between species
- Can be used to extrapolate animal results to humans
- Can aid in modeling Cr(VI) reduction in vivo

Measurement complexities

- Only possible to analytically measure **total** chromium *in vivo*
 - Total chromium = Cr(VI) + Cr(III)
- Oral ingestion of Cr(VI) leads to absorption of a Cr(VI)/Cr(III) **mixture** due to reduction
 - Difficult to know which form passes through the intestine
 - High red blood cell (RBC) to plasma ratios may indicate Cr(VI) uptake: RBCs rapidly absorb and reduce Cr(VI), “trapping” Cr(III)
- Dietary exposure to Cr(III) occurs in all species

Competing transport, reduction, and uptake



- Higher **total** chromium in body following Cr(VI) exposure, compared to Cr(III) exposure (NTP, 2008, 2010)
- Tissue chromium concentrations decrease distally (Kirman et al., 2012): **duodenum** > **jejunum** > **ileum**




PBPK models of chromium

- O'Flaherty (1996) PBPK model in rats
 - Calibrated to data from intravenous, gavage, inhalation, and drinking water (pre-1985 data)
 - Insufficient model for GI tract kinetics
 - Incorporated background Cr(III) exposure
- Kirman et al. (2012) PBPK model in rats and mice
 - Calibrated with new data, but drinking water studies only
 - Complex model for GI kinetics
 - Neglected background Cr(III) (subtracted concentrations of control from the exposure data)
- **This work attempts to reconcile differences and incorporate best science from both models**

Revision of GI kinetics





- **Original assumption:** One lumped component of the gastric juice is capable of reducing Cr(VI) to Cr(III)
 - Once this reducing agent is depleted (i.e., at high Cr(VI) levels) no more reduction can occur
- **Alternative assumption:** Two or three reducing agents exist in the gastric juice, each with different kinetic rates and capacities to reduce Cr(VI)
- These assumptions have implications when interpreting toxicological data
 - How much un-reduced Cr(VI) gets into the body?
 - What are the species differences?

Ex-vivo data in rats




**Original model
fails at high
concentration in
gastric juice**

Ex-vivo data in mice




Revised PBPK model

- Adapted from the model by Kirman et al. (2012)
- Revised GI kinetic model
- Simplified whole-body kinetics
 - More focus on GI, and total body burden
- Attempt to fit intravenous, gavage, and drinking water routes with consistent parameters
 - Incorporate background Cr(III) exposure in chronic studies







Intravenous data







Parameters for long-term retention and urinary elimination were fit to data by Mertz et al. (1965) (above) and Sayato et al. (1980)




Rat gavage Cr(III) data from NTP (2010)



Mouse gavage Cr(III) data from NTP (2010)






Rat data from Thomann et al. (1994)



Rats exposed to Cr(VI) in drinking water at 100 mg/L for 42 days, followed by ~100 days without exposure

Data points represent individual rat measurements [digitized by the study authors of Kirman et al. (2012)]

Mouse data from Kirman et al. (2012)



Mice exposed to Cr(VI) in drinking water at varying doses for 90 days.

Data points represent individual rat measurements [provided by Kirman et al. (2012)]


Data also adequately fit to:

- Kargacin et al. (1993) chronic drinking water data in rats and mice (liver, blood, lumped systemic tissues)

Additional modeling revisions:

- Added uptake of Cr(III) into GI tissues via plasma perfusion
- Most parameters are identical for both rats and mice
- All parameters are the same for all data sets
 - With exception of GI absorption, which is expected to vary with formulation and study



PBPK modeling of the NTP data



Challenges


- Rapid body weight and dose change
- 48-hour “wash-out” period
- Sacrifice time vs. final Cr(VI) dose
- Background Cr(III) exposure

Chronic NTP data used primarily as a validation







Body weight and dose curves





- Drinking water rate (thus mg/kg-d) and body weight functions incorporated into model
- High dose groups had different BW curve (not shown)



Dietary Cr(III) from NTP (mice): Day 182 sacrifice



Dietary Cr(VI) from NTP (mice): Day 371 sacrifice



Unanswered questions

- Uncertainties that go beyond idealized GI kinetics
 - Time variation in GI motility and secretions
 - Inter-individual variability in GI transporters for Cr(VI)
 - Variation of transporters along GI tract
 - Variation in diet and nutrition
 - Age susceptibilities
 - What about sites upstream of stomach?
 - Oral cavity, tongue, esophagus

Unanswered questions

- Best internal dose-metric for GI tract toxicity?
 - Amount of Cr(VI) absorbed
 - Amount of Cr(VI) escaping reduction in the stomach
 - Concentration of Cr(VI) in sensitive GI compartments
 - Rate of reduction (i.e., ROS generation) at sensitive sites
- Cr(VI) reduction webinar (Sep. 19 & 25 of this year)
 - Talks and discussions from many perspectives
 - Materials available at:
<http://www.epa.gov/iris/irisworkshops/cr6>

Acknowledgements

EPA/NCEA

Paul Schlosser
Catherine Gibbons
Susan Rieth
Ravi Subramaniam
Weihsueh Chiu
Paul White
Ted Berner
Vincent Cogliano
Lynn Flowers

External

Chris Kirman, Sean Hays, and
Deborah Proctor for providing
us their raw data and expertise

Cr(VI) Webinar team

Audrey Turley
Courtney Skuce
Maureen Johnson (EPA)

Panelists

Elaina Kenyon (EPA)
Gary Ginsberg
Kim Barrett
Max Costa
John Crison
Silvio De Flora
Sean Hays

Summary

- A harmonized PBPK model was developed for rodents
 - Adapted model by Kirman et al. (2012) to incorporate revised GI kinetics
 - Incorporated some features of O’Flaherty (1996) model
 - Model re-fit to data from additional routes of exposure
 - A model for humans is also under development
- Model will aid the evaluation of dose-response data for the IRIS Toxicological Review of Hexavalent Chromium
- Cr(VI) reduction webinar (Sep. 19 & 25 of this year)
 - Talks and discussions from many perspectives
 - Materials available at:
<http://www.epa.gov/iris/irisworkshops/cr6>